Priporočila za obravnavo bolnika s kronično obstruktivno pljučno boleznijo na primarni in specialistični pulmološki ravni v Sloveniji
DOI:
https://doi.org/10.6016/ZdravVestn.2471Ključne besede:
kronična obstruktivna pljučna bolezen (KOPB), priporočila, zdravljenje, diagnoza, poslabšanje KOPBPovzetek
Z dokumentom želimo smernice, ki jih predlaga GOLD, umestiti v slovenski prostor in opisati temelje obravnave te bolezni. Dokument naj bi služil čim bolj enotnemu oz. dogovorjenemu pristopu k obravnavi teh bolnikov.
Prenosi
Literatura
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary diseases 2017 report[cited 4.12.2016]. Available from: http://www.goldcopd.com/.
Šuškovič S, Košnik M. Nove smernice za trajno zdravljenje KOPB. Zdrav Vestn. 2013;82(7):530–532.
Šarc I, Jeric T, Ziherl K, Šuškovič S, Košnik M, Anker SD, et. al. Adherence to treatment guidelines and long-term survival in hospitalized patients with chronic obstructive pulmonary disease. J Eval Clin Pract. 2011 Aug;17(4):737–43.
World Health Report 2000 [cited 17.5.2016]. Available from: http://www.who.int/whr/2000/en.
Carpenter G, Bernabei R, Hirdes J. Building evidence on chronic disease in old age. BMJ. 2003;32(7234):528–9.
Freeman D, Nordyke RJ, Isonaka S, Nonikov DV, Maroni JM, Pride D,et al. Question for COPD diagnostic screening in a primary care setting. Respir Med. 2005;99(10):1311–8.
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Resp J. 2005 26(2):319–338.
Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Ofcial Statement of the European Respiratory Society. Eur Respir. 1993;16 Suppl 6:5–40.
van Dijk W, Tan W, Li P, Guo B, Li S, Benedetti A, et al. Clinical relevance of fxed ratio vs lower limit of normal of FEV1/FVC in COPD: patient reported outcomes form the canCOLD cohort. Annals of family medicine. 2015;13(1):41–8.
Güder G, Brenner S, Angermann CE, Ertl G, Held M, Sachs AP, et al. GOLD or lower limit of normal defnition. A comparison with expert based diagnosis of chronic obstructive pulmonary disease in prospective cohort study. Resp Res. 2012;13(1):13.
Lange P, Marrot JL, Vestbo J, Olsen KR, Ingebrigtsen TS, Dahl M, et al. Prediction of the clinical course of chronic obstrctive pulmonary disease, using the new GOLD classifcation: a study of the general population. Am J Respir Crit Care Med. 2012;186(10):975–81.
Fleržar M, Šuškovič S, Škrgat K, Košnik M. How to choose and interpret lung function tests in asthma and COPD. Zdrav Vestn. 2011;80(5):337–345.
Marčun R, Suštic A, Brguljan PM, Kadivec S, Farkaš J, Košnik M, et al. Cardiac biomarkers predict outcome afer hospitalisation for an acute exacerbation of chronic obstructive pulmonary disease. Int J Cardiol. 2012 29;161(3):156–9.
Regvat J, Žmitek A, Vegnuti M, Košnik M, Šuškovič S. Anxiety and depression during hospital treatment of exacerbation of chronic obstructive pulmonary disease. J Int Med Res. 2011;39(3):1028–38.
Bateman ED, Reddel HK, van Zyl–Smit RN, Agusti A. Te asthma-COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases? Lancet 2015;3:719–728.
Miravitlles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA, et al. Spanish Guideline for COPD (GesEPOC). Update 2014. Arch Bronconeumol 2014;50(Suppl 1):1–16.
Koblizek V, Chlumsky J, Zindr V, Neumannova K, Zatloukal J, Zak J, et al. Chronic obstructive pulmonary disease: ofcial diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient oriented care. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2013;157(2):189–201.
Anthoniesen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE, et al. Te effects of a smoking cessation intervention on 14.5-year mortality: a randomised clinical trial. Ann Intern Med 2005;142(4):233–9.
Lee PN, Fry JS. Systematic reviw of the evidence relating FEV1 decline to giving up smoking. BMC Med 2010;8:84.
Wedzicha JA, banerji D, Chapman KR,Vestbo J, Roche N, Ayers RT, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. NEJM 2016;374(23):2222-34.
Ferguson GT, Fležar M, Korn S, Korducki L, Grönke L, Abrahams R, et al. Efcacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis. Adv Ter. 2015;32(6):523–36.
Buhl R, Maltais F, Abrahams R, Bjermer L, Derom E, Ferguson G, Fležar M, Hébert J, McGarvey L, Pizzichini E, Reid J, Veale A, Grönke L, Hamilton A, Korducki L, Tetzlaff K, Waitere-Wijker S, Watz H, Bateman E. Tiotropium and olodaterol fxed-dose combination versus mono-components in COPD (GOLD 2–4). Eur Respir J. 2015;45(4):969–79.
Fležar M, Jahnz-Różyk K, Enache G, Martynenko T, Kristufek P, Škrinjarić-Cincar S, et al. SOSPES: SPIRIVA® observational study measuring SGRQ score in routine medical practice in Central and Eastern Europe. Int J Chron Obstruct Pulmon Dis. 2013;8:483–92.
Poplas Susič T, Švab I, Kersnik J. Projekt referenčnih ambulant v Sloveniji. Zdrav Vestn 2013;82(10):635–47.
Benedik B, Farkas J, Kosnik M, Kadivec S, Lainscak M. Mini nutritional assessment, body composition, and hospitalisations in patients with chronic obstructive pulmonary disease. Respir Med. 2011;105 Suppl 1:S38–43.
Lainscak M, von Haehling S, Doehner W, Sarc I, Jeric T, Ziherl K, Kosnik M, Anker SD, Suskovic S. Body mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease. J Cachexia Sarcopenia Muscle. 2011;2(2):81–86.
Gryparis A, Forsberg B, Katsouyanni K, Analitis A, Touloumi G, Schwartz J, Samoli E, Medina S, Anderson HR, Niciu EM, Wichmann HE, Kriz B, Kosnik M, Skorkovsky J, Vonk JM, Dörtbudak Z. Acute effects of ozone on mortality from the “air pollution and health: a European approach” project. Am J Respir Crit Care Med. 2004;170(10):1080–7.
Škrgat S, Šifrer F, Kopčavar Guček N, Osolnik K, Eržen R, et al. Stališče do obravnave akutnega poslabšanja KOPB. Zdrav Vestn. 2009;78(1):19–32.
Lainščak M, Kadivec S, Košnik M, Benedik B, Bratkovic M, Jakhel T, et al. Discharge coordinator intervention prevents hospitalizations in patients with COPD: a randomized controlled trial. J Am Med Dir Assoc. 2013;14(6):450.e1–6.
Geršak K, Fras Z, Rems M. Ali vemo, kakšne morajo biti dobre klinične smernice? Zdrav Vestn. 2016;85(1):6–14.
Fras Z, Robida A, Brubnjak-Jevtič V, Rems M, Jug B, Kersnik J, et al. Priročnik za smernice. Ljubljana: Ministrstvo za zdravje; 2003. p. 1–32.
Harbour R, Miller J, Scottish Intercollegiate Guidelines Network Grading Review Group. A new system for grading recommendations in evidence based guidelines. BMJ. 2001;323(7308):334-6.
Scottish Intercollegiate Guidelines Network. SIGN grading system 1999–2012. Edinburgh: Scottish Intercollegiate Guidelines Network, Healthcare Improvement Scotland; National Academy Press; 2014 [cited 2016 May 1]. Available from: http://www.sign.ac.uk/guidelines/fulltext/50/annexoldb.html
Objavljeno
Številka
Rubrika
Licenca
Avtor na prispevku, ki ga bo pripravil za Zdravniški vestnik, po pogodbi nanj prenaša vse materialne avtorske pravice, kakor izhajajo iz 22. člena Zakona o avtorski in sorodnih pravicah, in sicer pravico reproduciranja, pravico javnega izvajanja, pravico javnega prenašanja, pravico javnega predvajanja s fonogrami in videogrami, pravico javnega prikazovanja, pravico radiodifuznega oddajanja, pravico radiodifuzne retransmisije, pravico sekundarnega radiodifuznega oddajanja, pravico dajanja na voljo javnosti, pravico predelave, pravico avdiovizualne priredbe, pravico distribuiranja ter pravico dajanja v najem in vse druge pravice avtorja v skladu z ZASP.
Avtorjev prenos pravic po pogodbi je neizključen, velja za neomejeno število izdaj, za ves čas trajanja materialnih avtorskih pravic ter je prostorsko neomejen.
Avtor sme avtorsko delo tudi sam izkoriščati ali avtorske pravice prenašati na tretje osebe, vendar oboje šele po preteku 3 mesecev od prve objave dela v reviji Zdravniški vestnik.
Avtor Zdravniškemu vestniku izrecno dovoli, da lahko pravice, pridobljene v skladu s pogodbo prenaša naprej na tretje osebe brez omejitev.
Avtor se strinja, da Zdravniški vestnik prispevek objavi pod pogoji licence Creative Commons BY-NC 4.0 (navedba avtorstva-nekomercialno) ali primerljive licence.
